Core Points - Bragar Eagel & Squire, P.C. is investigating potential claims against AlloVir, Inc. on behalf of long-term stockholders following a class action complaint filed on March 19, 2024, concerning the period from March 22, 2022 to December 21, 2023 [2][7] - The investigation focuses on whether AlloVir's board of directors breached their fiduciary duties to the company [2] - The complaint alleges that AlloVir made materially false and misleading statements regarding its business and operations, particularly concerning the posoleucel Phase 3 studies [7] Company Details - AlloVir announced on December 22, 2023, that it would discontinue the posoleucel Phase 3 studies due to efficacy concerns, stating that pre-planned analyses indicated they would not meet their primary endpoints [7] - Following this announcement, AlloVir's stock price fell by $1.57 per share, or 67.38%, closing at $0.76 per share on December 22, 2023 [7]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against AlloVir, Inc. due to a class action complaint alleging that the company's board may have breached their fiduciary duties to shareholders during the specified class period [1][2]. Group 1: Allegations and Company Performance - The class action complaint alleges that AlloVir made materially false and misleading statements regarding its business operations and prospects, particularly concerning the posoleucel Phase 3 studies [2]. - It is claimed that the defendants failed to disclose that the posoleucel Phase 3 studies were unlikely to meet their primary endpoints, leading to an overstatement of the drug's efficacy and commercial prospects [2]. - Following the announcement on December 22, 2023, that AlloVir would discontinue the posoleucel Phase 3 studies due to efficacy concerns, the company's stock price plummeted by $1.57 per share, or 67.38%, closing at $0.76 per share [3]. Group 2: Legal and Contact Information - Long-term stockholders of AlloVir are encouraged to contact Bragar Eagel & Squire for discussions regarding their legal rights and potential claims [1][4]. - The law firm specializes in representing individual and institutional investors in complex litigation, indicating a focus on shareholder rights [5].